• Convertible Notes Issue Prospectus lodged today
  
• Independent Report on the Value to Virax of the Transgene Sub-licence
  
• Appointment of Dr Larry Ward as CEO
  

Prospectus
Today a Prospectus was lodged for a Pro Rata Rights Issue of Convertible Notes to raise $2.7 million.

Details of the Rights Issue are included in a concurrent ASX Appendix 3B announcement.

Click here for Prospectus (PDF)
Click here for Appendix 3B (PDF)

Valuation of Transgene Sub-licence
An independent report has been received that ascribes a value of the Co-X-Gene™ technology sub-licence granted by Virax to the French immunotherapy company Transgene SA.

A copy of the report will be posted on the Company’s website (www.virax.com.au) or a copy may be requested from Virax.

Click here for Virax License Valuation (PDF)

Appointment of Dr Larry Ward as CEO
The Board takes great pleasure in announcing the appointment of Dr Larry Ward as CEO of the Company. This appointment follows the resignation of Dr David Beames which was effective upon the lodgement of the Prospectus mentioned above.

Dr Ward has been with the Company since 2000 and previously has overseen the technical development of the therapeutic vaccines and the clinical trials as Development Director.

Dr Beames remains a non-executive director of the Company


About Virax
Virax, based in Melbourne, Australia, is a biopharmaceutical company engaged in the discovery and development of novel immunotherapeutic products for the treatment of cancer, and chronic infectious diseases. The Company’s lead product, VIR201, an HIV/AIDS immunotherapeutic (therapeutic vaccine), recently cleared by the U.S. FDA to begin Phase II trials, has completed two successful clinical trials in Australia with additional, international studies planned. The Company has also submitted an application to the South African regulatory authority (MCC) to conduct a Phase I/IIa trial of VIR201. Funding for the African trial has been contributed by a consortium of global and South African resource companies led by BHP Billiton.

Virax’s second product in development, VIR501, is an immunotherapeutic for the treatment of late stage hormone refractory prostate cancer. The Company has completed GMP production and ready to commence clinical trials upon receipt of appropriate funding.

The Company has licensed its Co-X-Gene™ technology to Transgene S.A. of Strasbourg, France for use in the USA and Canada for its immunotherapeutic products -TG 4001 and TG - 4010.

Virax continues to work on financial and strategic matters to develop potential partnering arrangements and financing options.

For further information contact:
Dr Larry Ward
CEO, Virax Holdings Limited
Melbourne, Australia
(03) 9854 6230

John Morrison
CFO, Virax Holdings Limited
Melbourne, Australia
(03) 9854 6230